Illumina, Inc. (NASDAQ:ILMN – Get Free Report) Director Keith Meister sold 285,238 shares of Illumina stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $213.86, for a total value of $61,000,998.68. Following the completion of the transaction, the director owned 1,709,187 shares in the company, valued at approximately $365,526,731.82. This represents a 14.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Illumina Trading Up 2.9%
Shares of NASDAQ ILMN traded up $6.16 during mid-day trading on Friday, hitting $219.40. The stock had a trading volume of 1,917,079 shares, compared to its average volume of 2,061,622. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $220.43. The business has a 50 day moving average price of $188.01 and a two-hundred day moving average price of $152.44. The firm has a market cap of $33.13 billion, a P/E ratio of 40.93, a price-to-earnings-growth ratio of 3.00 and a beta of 1.45.
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter last year, the business posted $1.19 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.
Hedge Funds Weigh In On Illumina
Analysts Set New Price Targets
Several equities analysts have commented on ILMN shares. TD Cowen raised their price objective on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Leerink Partners upped their price objective on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. JPMorgan Chase & Co. lifted their price target on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and an average target price of $188.40.
Read Our Latest Stock Report on Illumina
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Articles
- Five stocks we like better than Illumina
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
